直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 118614
著者
Kondo, Yoshihiro National Hospital Organization Kochi Hospital
國重, 道大 National Hospital Organization Kochi Hospital
Kadota, Naoki National Hospital Organization Kochi Hospital
Okano, Yoshio National Hospital Organization Kochi Hospital
Machida, Hisanori National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo National Hospital Organization Kochi Hospital
Naruse, Keishi National Hospital Organization Kochi Hospital
Takeuchi, Eiji National Hospital Organization Kochi Hospital
キーワード
durable response
immune-related hepatitis
non-small cell lung cancer
pembrolizumab
single dose
資料タイプ
学術雑誌論文
抄録
Profound and durable responses to a single dose of pembrolizumab in lung cancer are rare. We encountered a non-small cell lung cancer patient showing a deep and durable response with a single dose of pembrolizumab. A 79-year-old man reported bloody sputum for several weeks and visited a general physician. A chest x-ray revealed a tumor shadow in the right middle lung field at that time, and the patient was referred to our hospital. He was diagnosed with adenocarcinoma of the lung by transbronchial biopsy. The expression of programmed death ligand 1 in tumor cells was 100% by immunostaining. Based on the above, immunotherapy with pembrolizumab was performed as first-line therapy. Cancer cells had significantly shrunk at the end of the first cycle. The patient had grade-3 immune-related hepatitis at the end of the first cycle. Pembrolizumab treatment was stopped and prednisolone (80 mg/body) was initiated. Subsequently, liver function normalized, and prednisolone was tapered and discontinued. Since then, no tumor recurrence has been detected for 1.5 years without treatment. There have been few reports of profound and durable responses to a single dose of pembrolizumab in lung cancer. The results indicate that a single dose of pembrolizumab alone may be sufficient to cause durable response and serious immune-related adverse events in some cases.
掲載誌名
Thoracic Cancer
ISSN
17597714
17597706
出版者
China Lung Oncology Group|John Wiley & Sons Australia
13
4
開始ページ
648
終了ページ
652
発行日
2022-01-12
権利情報
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系